- Preimplantation genetic haplotyping
Preimplantation Genetic Haplotyping (PGH) is a clinical method of
preimplantation genetic diagnosis (PGD). PGH was first developed in 2006 atLondon 'sGuy's Hospital and greatly advances PGD by usingDNA fingerprinting rather than identifying the actual genetic signature (such aspoint mutation s).cite journal
author = Renwick PJ, Trussler J, Ostad-Saffari E, et. al
date = 2006-07-13
title = Proof of principle and first cases using preimplantation genetic haplotyping--a paradigm shift for embryo diagnosis
journal = Reprod Biomed Online
volume = 13
issue = 1
pages = 110–9
doi =
pmid = 16820122
url = http://www.ingentaconnect.com/content/repro/rebi/2006/00000013/00000001/art00017
format = subscription required ]Scope
Compared with previous PGD techniques, PGH allows:
* The ability to screen male
embryo s
**hence male embryos can be screened forX-linked disorders such asDuchenne muscular dystrophy andBecker's muscular dystrophy
**hence having both male and female embryos screened, an increase the number of embryos that can be implanted
* A much greater number of individual tests
* Increased reliability
* Higher success rateUses
PGH has been used to screen for:
*cystic fibrosis
*Duchenne muscular dystrophy
*Huntington's disease
*Spinal Muscular Atrophy
*Alport's syndrome
*Von Hippel-Lindau disease
*Sickle-cell disease
* and recurrentHydatidiform mole References
External links
cite web
url = http://www.guysandstthomas.nhs.uk/news/newsarchive/newsarticles/pgd.aspx
title = Revolutionary new technology will allow more couples to benefit from preimplantation genetic diagnosis
accessdate = 2006-09-26
date = 2006-09-12
work = PGH Press Release
publisher = 2006 Guy's and St Thomas' NHS Foundation Trust
Wikimedia Foundation. 2010.